초록 ▼

The present invention relates to a vessel for withdrawing blood, the vessel containing a solution which comprises a guanidinium salt, a buffer substance, a reducing agent, and/or a detergent as components. The vessel is particularly suited for withdrawing blood which is to be analyzed with respect t

The present invention relates to a vessel for withdrawing blood, the vessel containing a solution which comprises a guanidinium salt, a buffer substance, a reducing agent, and/or a detergent as components. The vessel is particularly suited for withdrawing blood which is to be analyzed with respect to nucleic acids.

대표청구항 ▼

1. A blood withdrawing vessel containing a nucleic acid-stabilizing aqueous solution for stabilizing nucleic acids in the withdrawn blood directly upon contact with the solution, the solution comprising the following components:a guanidinium salt in a concentration of 1 to 8.0 M;a buffer substance i

1. A blood withdrawing vessel containing a nucleic acid-stabilizing aqueous solution for stabilizing nucleic acids in the withdrawn blood directly upon contact with the solution, the solution comprising the following components:a guanidinium salt in a concentration of 1 to 8.0 M;a buffer substance in a concentration of 10 to 300 mM;a reducing agent in a concentration of 0.1 to 10%, by wt; anda detergent in a concentration of 5 to 30%, by wt. 2. The vessel according to claim 1, characterized in that the guanidinium salt is selected from guanidinium thiocyanate and guanidinium chloride. 3. The vessel according to claim 1, characterized in that the guanidinium salt is present in a concentration of 2.5 to 8.0 M. 4. The vessel according to claim 1, characterized in that the buffer substance is selected from Tris, HEPES, MOPS, citrate and phosphate buffer. 5. The vessel according to claim 1, characterized in that the detergent is selected from Triton-X-100, NP-40, polydocanol and Tween 20. 6. The vessel according to claim 1, characterized in that the reducing agent is selected from dithiothreitol, β-mercaptoethanol and TCEP. 7. The vessel according to claim 1, characterized in that the pH of the solution is between 4.0 and 7.5. 8. The vessel according to claim 1, characterized in that the solution contains the following components:4 m guanidinium thiocyanate;45 mM Tris/HCl;15% (w/v) Triton-X-100;0.8% (w/v) DTT,wherein the PH is at 6.0. 9. The vessel according to claim 1, characterized in that it has a vacuum in the chamber which is provided for receiving blood. 10. The vessel according to claim 1, characterized in that it contains withdrawn blood. 11. A method of withdrawing blood, comprising the step of directly introducing the blood into a vessel according to claim 1. 12. The method according to claim 11, characterized in that an amount of blood is withdrawn that is 0.1 to 4 times the volume of the solution in the vessel. 13. The method according to claim 12, characterized in that the concentration of the guanidinium salt after the blood is introduced is between 1.0 M and 5 M. 14. A method for stabilizing and/or isolating nucleic acids from blood, comprising the step of introducing blood into a vessel according to claim 1 and, optionally, isolating the nucleic acids with conventional methods. 15. The method according to claim 11, characterized in that the pH of the solution is adjusted such that, following the introduction of the blood, a pH between 4.0 and 7.5 is obtained. 16. The vessel according to claim 7, characterized in that the pH of the solution is between 4.0 and 6.5. 17. The method according to claim 13, characterized in that the concentration of the guanidinium salt, after blood is introduced, is between 1.5 and 5 M. 18. A blood withdrawing vessel containing a nucleic acid-stabilizing aqueous solution for stabilizing nucleic acids in the blood directly upon contact with the solution, the solution comprising the following components:a guanidinium salt in a concentration of 1 to 8.0 M;a buffer substance in a concentration of 10 to 300 mM;a reducing agent in a concentration of 0.1 to 10%, by wt. 19. The vessel according to claim 18, characterized in that the guanidinium salt is selected from guanidinium thiocyanate and guanidinium chloride. 20. The vessel according to claim 19, characterized in that the guanidinium salt is present at a concentration of 2.5 to 8.0 M. 21. The vessel according to claim 18, characterized in that the buffer substance is selected from Tris, HEPES, MOPS, citrate and phosphate buffer. 22. The vessel according to claim 18, characterized in that the reducing agent is selected from dithiothreitol, β-mercaptoethanol and TCEP. 23. The vessel according to claim 18, characterized in that the pH of the solution is between 4.0 and 7.5. 24. The vessel according to claim 23, characterized in that the pH of the solution is between 4.0 and 6.5. 25. The vessel according to claim 18, characterized in that it has a vacuum in the chamber which is provided for receiving blood. 26. The vessel according to claim 18, characterized in that it contains withdrawn blood. 27. A method of withdrawing blood, comprising the step of directly introducing the blood into a vessel according to claim 18. 28. The method according to claim 27, characterized in that an amount of blood is withdrawn that is 0.1 to 4 times the volume of the solution in the vessel. 29. The method according to claim 28, characterized in that the final concentration of the guanidinium salt after blood supply is between 1.0 M and 5 M. 30. The method according to claim 29, characterized in that the final concentration of the guanidinium salt after blood supply is between 1.5 M and 5 M. 31. The method according to claim 29, characterized in that the pH of the solution is adjusted such that, following the addition of the sample material, a pH between 4.0 and 7.5 is obtained. 32. A method for stabilizing and/or isolating nucleic acids from blood, comprising the step of introducing blood into a vessel according to claim 18 and, optionally, isolating the nucleic acids with conventional methods. 33. A stabilized blood sample obtainable by introducing whole blood into a vessel according to claim 18. 34. The blood sample according to claim 33, characterized in that it has a pH of 4.0 to 7.5. 35. The blood sample according to claim 34, characterized in that it has a pH of 6.6 to 7.0. 36. The blood sample according to claim 33, characterized in that it is derived from human blood. 37. A blood withdrawing vessel containing a nucleic acid-stabilizing aqueous solution for stabilizing nucleic acids in the withdrawn blood directly upon contact with the solution, the solution comprising the following components:a guanidinium salt in a concentration of 1 to 8.0 M;a buffer substance in a concentration of 10 to 300 mM;a detergent in a concentration of 5 to 30%, by wt. 38. The vessel according to claim 37, characterized in that the guanidinium salt is selected from guanidinium thiocyanate and guanidinium chloride. 39. The vessel according to claim 38, characterized in that the guanidinium salt is present at a concentration of 2.5 to 8.0 M. 40. The vessel according to claim 37, characterized in that the detergent is selected from Triton-X-100, NP-40, polydocanol and Tween 20. 41. The vessel according to claim 37, characterized in that the buffer substance is selected from Tris, HEPES, MOPS, citrate and phosphate buffer. 42. The vessel according to claim 37, characterized in that the reducing agent is selected from dithiothreitol, β-mercaptoethanol and TCEP. 43. The vessel according to claim 37, characterized in that the pH of the solution is between 4.0 and 7.5. 44. The vessel according to claim 43, characterized in that the pH of the solution is between 4.0 and 6.5. 45. The vessel according to claim 37, characterized in that it has a vacuum in the chamber which is provided for receiving blood. 46. The vessel according to claim 37, characterized in that it contains withdrawn blood. 47. A method of withdrawing blood, comprising the step of directly introducing the blood into a vessel according to claim 37. 48. The method according to claim 47, characterized in that an amount of blood is withdrawn that is 0.1 to 4 times the volume of the solution in the vessel. 49. The method according to claim 48, characterized in that the final concentration of the guanidinium salt after blood supply is between 1.0 M and 5 M. 50. The method according to claim 48, characterized in that the final concentration of the guanidinium salt after blood supply is between 1.5 M and 5 M. 51. The method according to claim 37, characterized in that the pH of the solution is adjusted such that, following the addition of the sample material, a pH between 4.0 and 7.5 is obtained. 52. A method for stabilizing and/or isolating nucleic acids from blood, comprising the step of introducing blood into a vessel according to claim 37 and, optionally, isolating the nucleic acids with conventional methods. 53. A stabilized blood sample obtainable by intro ducing whole blood into a vessel according to claim 37. 54. The blood sample according to claim 53, characterized in that it has a pH of 4.0 to 7.5. 55. The blood sample according to claim 53, characterized in that it has a pH of 6.6 to 7.0. 56. The blood sample according to claim 53, characterized in that it is derived from human blood.